Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Pharming Group N.V.NASDAQ: PHAR

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 90.8%

Gross margin was 90.8% in Q1 FY2026, up 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 87.3%, down 1.7 pp year over year. Over 3 fiscal years it narrowed by 3.6 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
90.8%+13.7 pp QoQ
Last fiscal yearDec 2025
87.9%-0.2 pp YoY
LTMMar 2026
87.3%-1.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.4 pp——
1 year-0.2 pp——
3 years-3.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
87.9%
Year-over-year change
-0.2pp

Gross Margin vs competitors

How PHAR compares with its peers on the latest reported figures

  • PHAR's LTM Mar 2026 gross margin of 87.3% is the 4th highest of the 8 companies compared; the peer median is 79.9%.
  • Its year-over-year change of -1.7 pp is the 4th highest of 7, against a peer median of -5.2 pp.
  • Over three fiscal years its change of -3.6 pp compares with a peer median of +0.3 pp.
PHAR Competitors Peer median
Gross Margin for PHAR and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
STOKStoke Therapeutics, Inc.LTM Mar 202690.4% -9.1 pp+0.0 pp
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
PHARPharming Group N.V.LTM Mar 202687.3% -1.7 pp-3.6 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 202679.9% -1.4 pp+1.1 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 202623.5% -73.5 pp+0.3 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
PHVSPharvaris N.V.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding PHAR) 79.9%-5.2 pp+0.3 pp

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue225.46M205.62M245.32M307.75M377.18M
Cost of Revenue23.97M17.56M25.21M36.66M45.63M
Gross Profit201.49M188.06M220.1M271.09M331.56M
Gross Margin89.4%91.5%89.7%88.1%87.9%
Research & Development79.78M52.53M68.91M86.1M98.08M
Selling, General & Admin54.56M68.85M87.5M102.74M117.44M
Operating Expenses186.12M169.83M225.49M280.02M309.75M
Depreciation & Amortization22.23M13.19M15.93M16.64M10.76M
EBITDA55.3M33.53M9.88M16.89M31.7M
EBITDA Margin24.5%16.3%4.0%5.5%8.4%
Operating Income15.37M18.23M(5.39M)(8.93M)20.88M
Operating Margin6.8%8.9%-2.2%-2.9%5.5%
Interest Income59.99K85K3.53M5.92M2.56M
Interest Expense7M5.36M5.96M9.05M21.31M
Other Income / Expenses10.79M(3.25M)(6.63M)133.58K(8.03M)
Income Before Tax26.16M14.99M(12.01M)(8.79M)12.88M
Pre-Tax Margin11.6%7.3%-4.9%-2.9%3.4%
Income Tax Expense8.03M1.31M(1.46M)3.47M10.34M
Net Income18.13M13.67M(10.55M)(12.26M)2.86M
Net Margin8.0%6.7%-4.3%-4.0%0.8%
EPS (Basic)0.230.17(0.14)(0.18)0.04
EPS (Diluted)0.210.16(0.14)(0.18)0.04
Weighted Avg Shares87.64M82.54M65.7M68.92M71.32M
Weighted Avg Shares (Diluted)87.64M84.28M65.7M68.92M71.32M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.